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Susceptibility testing for common, complex adult-onset diseases is
projected to become more commonplace as the rapid pace of genomic
discoveries continues, and evidence regarding the potential benefits and
harms of such testing is needed to inform medical practice and health
policy. Apolipoprotein E (APOE ) testing for risk of Alzheimer’s disease
(AD) provides a paradigm in which to examine the process and impact of
disclosing genetic susceptibility for a prevalent, severe and incurable
neurological condition. This review summarizes findings from a series of
multi-site randomized clinical trials examining psychological and
behavioral responses to various methods of genetic risk assessment for AD
using APOE disclosure. We discuss challenges involved in disease risk
estimation and communication and the extent to which participants
comprehend and perceive utility in their genetic risk information. Findings
on the psychological impact of test results are presented (e.g. distress),
along with data on participants’ health behavior and insurance purchasing
responses (e.g. long-term care). Finally, we report comparisons of the
safety and efficacy of intensive genetic counseling approaches to briefer
models that emphasize streamlined processes and educational materials.
The implications of these findings for the emerging field of personal
genomics are discussed, with directions identified for future research.
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Background
Genetic susceptibility testing for common, complex
diseases
Genomic discoveries are transforming medical
science, in part by providing new methods to
predict the occurrence (1) or progression (2) of
diseases that have a genetic basis. Because of
their public health significance, there has been
great interest in the identification of susceptibility
genes for common, complex conditions in par-
ticular. Genetic susceptibility testing for common
disease provides information about risk that is,
by definition, influenced by a complex (and not
always understood) interplay among genes, envi-
ronment and behavior. This type of information
lacks the degree of certainty of highly pene-
trant Mendelian variants, where the presence or
absence of specific mutations is more clearly asso-
ciated with the future manifestation (or not) of a
given disease. Because of their limitations, there
is concern that many new tests are prematurely
moving into the clinical arena and the direct-
to-consumer (DTC) marketplace (3, 4). Skeptics
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express concerns over the limited predictive value
of genetic susceptibility testing, along with poten-
tial harms including psychological distress, mis-
understanding of risk information, and insurance
or employment bias (5, 6). On the other hand,
personalized disease management and pharma-
ceutical regimens tailored to individuals’ geno-
types represent promising applications of genomics
research (7, 8). Experts forecast that genomic
discoveries will increase options for prevention
and treatment of common, complex health con-
ditions such as diabetes, heart disease, and can-
cer (9). Some contend that personalized genomic
risk information can help prompt individuals to
make lifestyle changes to avoid or reduce their
disease risk (10).
Although there is much debate over the like-
lihood and extent of benefits to be derived from
genetic susceptibility testing, it appears clear that
the use of this modality will increase in the com-
ing years. Such markers can often be measured
with relative ease once identified and the initiative
of motivated individuals and the power of market
forces may make it difficult to limit or prevent
the widespread use of susceptibility genotyping
in the future. Our responsibility as experts may
be to understand how to use them wisely and to
articulate whether and under what circumstances
they should be used. Clinical research, as opposed
to ideologically based speculation, would seem to
be the best guide of policy and practice in this
arena. Given the vast number of genetic markers
and conditions to consider, one research strategy
is to select ‘sentinel’ cases where genetic suscepti-
bility testing for common, adult-onset conditions is
available. This has been our approach, as we have
used genetic susceptibility testing for Alzheimer’s
disease as a paradigm in which to examine the
process and impact of disclosing genetic risk infor-
mation to asymptomatic adults.
Genetic testing for Alzheimer’s disease
Alzheimer’s disease (AD) is the most common
type of dementia in the United States, with a preva-
lence expected to increase dramatically in com-
ing decades (11). The genetics of AD have been
comprehensively summarized elsewhere. Briefly,
mutations in each of three genes (APP, PS1 and
PS2 ) are associated with early onset, autosomal
dominantly inherited forms of AD. Genetic test-
ing already occurs for these rare familial forms
of AD, with counseling procedures based on the
Huntington’s disease testing model (12). However,
these mutations account for a very small propor-
tion of AD cases. Much more common is a variant
of the susceptibility polymorphism Apolipoprotein
E (APOE ), a plasma protein involved in choles-
terol transport. APOE has three common alleles
(ε2, ε3 or ε4). The ε4 allele is a robust risk factor
for sporadic and late-onset familial AD, with the
degree of risk varying depending upon whether the
individual carries one or two ε4 alleles (13). Dis-
coveries of new susceptibility genes over the past
decade (14, 15) have increased our knowledge of
potential genetic determinants of AD, but none of
these has been as frequently replicated nor has as
notable a risk effect as APOE.
In the mid- to late 1990s, several expert consen-
sus statements cautioned against the clinical use
of predictive testing for AD using APOE, largely
because of the fact that information about the
future risk of developing AD does not change clini-
cal care given the limited treatment and prevention
options for the disease (16–19). In addition, pos-
session of an ε4 allele is neither necessary nor
sufficient to cause AD. However, each of the afore-
mentioned statements concluded along these lines:
‘More research is needed on how individuals and
families understand complex probabilistic genetic
information and on the implications of living one’s
life “at risk” for developing AD’ (19).
Research on genetic susceptibility testing for AD
may be useful for understanding how individuals
will respond to susceptibility testing for common,
complex diseases in general. Genetic risk factors
now being identified for other complex diseases
via genome-wide association studies are similar
to APOE in which (i) they are more prevalent
in the general population than rare Mendelian
variants, (ii) their positive predictive value is
relatively low, and (iii) testing for these variants
is now being marketed to the public through
commercial firms. Although its lack of proven
prevention options sets AD apart from modifiable
conditions such as heart disease and diabetes, there
is growing scientific evidence that environment,
lifestyles, and social factors may influence risk of
AD and related dementias (11, 20). The majority
of the public believes that lifestyle, diet, and
mental inactivity contribute to AD risk even
while they endorse genetics as the most important
risk factor for AD (21). Furthermore, individuals
who seek genetic susceptibility testing for AD
commonly cite disease risk reduction as a prime
motivator (22). In sum, laypersons appear to
view AD as more ‘modifiable’ than current
scientific evidence suggests. In the next section,
we describe a series of clinical trials designed
to examine the psychological and behavioral
impact of providing genetic susceptibility testing
for AD.
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Table 1. Overview of REVEAL clinical trials
Trial Dates Site locations Study sample Main question(s)
REVEAL I 2000–2003 Boston
Cleveland
New York City
162 Adult children of
people with AD
What is the psychological impact of
disclosure of genetic risk for AD?







Can genetic risk for AD be
disclosed safely and effectively
using a condensed protocol?




257 Adults with and
without immediate
AD family history
What is the impact of disclosure of
pleiotropic disease risks
associated with APOE? Can
results be disclosed safely and
effectively via phone?





MCI and their study
partners
What is the impact of disclosing
APOE to a population at
imminent risk of AD?
AD, Alzheimer’s disease; APOE, apolipoprotein E; REVEAL, Risk Evaluation and Education for Alzheimer’s Disease.
Disclosing genetic risk for AD: the REVEAL
Study
Overview
The Risk Evaluation and Education for Alzheimer’s
Disease (REVEAL) Study is a series of multi-
site randomized clinical trials that examines the
impact of APOE genetic susceptibility testing on
asymptomatic individuals (Table 1). An interdis-
ciplinary team of clinicians, geneticists, genetic
counselors, health psychologists, ethicists and pol-
icy scholars created protocols to evaluate the
impact of APOE disclosure for evaluating AD
risk. The first REVEAL Study trial compared a
genetic risk assessment program that incorporated
APOE genotype disclosure against a more gen-
eral AD risk assessment. The second trial built
on the first by expanding the participant profile to
include more African Americans and to test a con-
densed educational and counseling protocol against
a more traditional model based on genetic testing
for cancer susceptibility. The third trial explored
the impact of disclosing that the ε4 allele of APOE
is associated with coronary artery disease in addi-
tion to AD and also tested a telephone disclosure
protocol against in-person disclosure. The fourth
trial, just underway, is exploring the impact of an
AD genetic risk assessment for individuals already
with mild cognitive impairment (MCI).
In each trial, participants complete a baseline
assessment and then receive pre-test education
about study requirements and the risk information
that will be disclosed. Following a blood draw for
genotyping purposes, participants receive person-
alized AD risk estimates through age 85 (range:
6–77%) depending on gender, self-identified eth-
nicity (REVEAL II and III, only), family history
of AD and, for most participants, APOE geno-
type. These risks were derived from a longstand-
ing multi-site program of genetic epidemiology
research (23). Participants are followed 1 year to
assess the impact of the risk assessment on out-
comes described below.
Risk estimation
As is the case with other complex diseases, AD eti-
ology poses numerous challenges for risk estima-
tion. Although individual studies have suggested
scores of potential risk and protective factors for
AD, many have not been confirmed in prospective
studies and it is unclear whether and to what extent
these risk factors are additive or interactive. The
risk estimates developed in REVEAL were there-
fore based only on well-established AD risk factors
including age, gender, family history, and APOE
genotype using (i) sex- and family history-specific
incidence curves based on a large-scale epidemio-
logical study (24) and (ii) APOE genotype-specific
odds ratio estimates from a meta-analysis of data
over 50 studies worldwide (25). However, our esti-
mates did not take into account other potential
risk factors for the disease, including other genes,
gene–gene interactions, gene–environment inter-
actions, environmental exposures, and other demo-
graphics factors. Participants were notified of these
limitations during pre-test education and when dis-
closed their risk of AD.
Another challenge was the issue of differing
risks across racial and ethnic groups. Several
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epidemiological studies have suggested that African
Americans are at higher risk than Whites, but
the underlying reasons for this disparity are not
fully understood. Whether and how to disclose
ethnicity-specific risk estimates raised both sci-
entific and ethical dilemmas given the troubled
history of genetic research with African Americans
(26). Guided by both expert consensus and focus
group data from African American community
members, risk models specific to ethnicity, gender,
and APOE genotype were subsequently developed
for the second REVEAL trial such that African
Americans and Whites received differing risk esti-
mates (Table 2) (27). The experience of risk esti-
mation in REVEAL offers lessons for how to
address the ambiguity and ethical tensions inher-
ent in risk disclosure for a complex disease whose
etiology is not well-understood.
Interest in testing
The REVEAL Study has shed light on those who
might express interest in genetic susceptibility test-
ing for common complex disease. Among partic-
ipants in the first REVEAL trial who had been
recruited from research registries, those who were
under the age of 60 and those who were college
educated were more likely to progress from ini-
tial contact to randomization. Among participants
who self-referred to the study after hearing about
it in a memory assessment clinic, the media, or in
a public presentation, the average education level
was more than a college degree and 79% were
female (28). Although some of these trends may
be driven by the characteristics of Alzheimer’s dis-
ease rather than the characteristics of testing (e.g.
the need to plan for AD in middle age and gender
disparities in AD caregiving), differences by gen-
der and education have also been seen to a lesser
Table 2. Lifetime risk estimates (through age 85) for first-
degree relatives of people with AD, stratified by gender, APOE










ε2/ε3a 13 19 33 36
ε3/ε3 18 29 41 49
ε2/ε4 25 49 48 69
ε3/ε4 29 52 56 73
ε4/ε4 56 57 77 74
AA, African American; AD, Alzheimer’s disease; APOE,
apolipoprotein E.
aε2/ε2 estimates are not provided because there was not
sufficient prevalence of this genotype in our epidemiological
studies to provide robust risk estimates.
extent in other studies of genetic susceptibility test-
ing (29, 30).
Perceived utility of testing
As mentioned above, genetic testing in clinical
practice is typically judged on whether or not it
can inform medical care options. However, our
findings showed that participants had numerous
reasons for seeking testing that would not be clas-
sified under usual definitions of clinical utility. For
example, the vast majority of participants endorsed
reasons for seeking testing that included the fol-
lowing: arranging personal affairs, informing deci-
sions about long-term care insurance, preparing the
family for the possibility of illness, and emotional
relief if found to be at lower risk (31). Of note,
here are the perceived benefits of genetic testing
for psychological well-being and advanced plan-
ning; many participants believed that information
would be helpful even in the absence of proven
medical care options to reduce their AD risk.
Risk recall and perceptions
Our experience also showed the challenges in con-
veying genetic risk information for a complex dis-
ease. Informed by the health risk communication
literature, our counseling and education materials
included the following: take-home written materi-
als to reinforce information presented (32), strate-
gies for coping with risk and resources for further
information, and graphical representations of risk
information to guide in-person counseling (33).
For example, we used visual aids including risk
curves specific to gender, ethnicity, family his-
tory and APOE genotype that conveyed risk of
AD through age 85 and in comparison to refer-
ence groups including the general population (34).
These curves also showed risk over time, reinforc-
ing the importance of the interactive effect between
age and APOE (Fig. 1). Yet even despite these
efforts and a well-educated set of participants,
many could not recall their lifetime risk infor-
mation at a 6-week follow-up. However, the vast
majority knew their APOE status, suggesting that
genotype is more memorable to participants than
lifetime risk and reinforcing the notion that gist-
level health information is often retained instead
of specific numeric estimates (35).
Results also suggested that genotype informa-
tion has an outsized influence on risk perceptions,
even when offered within a multi-factorial risk
assessment. For example, we compared women
with ε4-negative test results to a control group
of women who received an identical lifetime risk
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Fig. 1. Sample risk curve presented to REVEAL par-
ticipants. REVEAL, Risk Evaluation and Education for
Alzheimer’s Disease.
estimate but who were not disclosed their APOE
status. Although both groups received the same
‘take-home’ message about lifetime risk of AD
(i.e. 29% probability), the ε4-negative women per-
ceived their risk as lower, reported testing as
having a more positive impact, endorsed less
strongly the belief that they might develop AD,
and reported a greater reduction in anxiety about
AD (Fig. 2) (36). Ongoing analyses in REVEAL
are continuing to explore the extent to which ‘neg-
ative’ genetic test results contribute to a potentially
false sense of reassurance about disease risk.
Data also suggest that calculated risk estimates
are often not taken at face value. Approximately
half of the participants in the second REVEAL
trial who could accurately recall their numerical
risk estimates asserted that their lifetime risk
for AD was either lower or higher than what
was calculated (37). Some participants appeared
to be ‘anchored’ to their initial, pre-test AD risk
perceptions. Others may have adjusted for personal
risk or protective factors not accounted for in our
risk estimates.

































Family history + ε3/ε3 genotype
Fig. 2. Proportion of participants receiving identical 29%
numerical risk estimates that endorsed perceived risk survey
items, stratified by risk disclosure group.
Psychological impact of APOE disclosure
A prominent concern about genetic testing for AD
is the potential of psychological harm when dis-
closing risk information for a severe, incurable
disorder (18). In our first trial, clinical symptoms
of anxiety, depression and test-related distress
were assessed up to 1 year following disclosure
using validated self-reported measures, including
the Beck Anxiety Inventory (38), Center for Epi-
demiologic Studies-Depression Scale (39), and the
Impact of Events Scale (40), respectively. Results
showed no difference in changes in the time-
averaged measures between the intervention (risk
assessment with APOE genotype disclosure) and
control (risk assessment without APOE disclo-
sure) arms. Secondary comparisons between those
receiving ε4-positive results and controls also
found no significant differences. Results suggest
that APOE genotype disclosure under carefully
controlled circumstances to adult children of per-
sons with AD did not pose significant psycholog-
ical risks, even for those who learned they were
ε4-positive (41). These results are largely consis-
tent with studies of the impact of genetic testing
for other adult-onset disorders such as Hunting-
ton’s disease and hereditary cancer syndromes;
this research suggests that (i) baseline psycholog-
ical functioning is a better predictor of post-test
response than the actual test result itself and (ii)
test-specific distress, while sometimes significant,
is usually transient if patients are provided proper
post-test counseling (42, 43). It should be pointed
out, however, that these results may not generalize
to current modes of APOE disclosure that are now
occurring via DTC genetic testing companies. The
latter model not only lacks in-person counseling
but also discloses APOE information simultane-
ously with risks for numerous other conditions.
This format would seemingly raise the chances that
ε4-positive results could come ‘out of the blue’
and thereby prove more psychologically distress-
ing than as observed in our studies.
Behavioral impact of disclosure
Genetic risk information alone is typically insuffi-
cient to engender complex behavior changes such
as smoking cessation and modification of dietary
and exercise habits (42, 44). However, some stud-
ies suggest that genetic risk information may
enhance patient preferences for biological inter-
ventions (e.g. medications) over health behavior
changes (e.g. lifestyle changes) (45–47). Indeed,
in the first two REVEAL trials, the most common
health behavior change reported by participants
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was the addition of vitamins or nutritional sup-
plements (e.g. vitamin E) (48). This finding may
suggest a need to scrutinize emerging commercial
services that are using genetic test results to market
nutriceuticals of unproven benefit.
Another domain of interest was purchasing of
long-term care (LTC) insurance. LTC insurance is
relevant because AD often results in nursing home
placement and lengthy inpatient stays. In our first
trial, ε4-positive participants were approximately
four times more likely than controls to report
LTC insurance changes during the 1-year follow-
up (Fig. 3) (49), a finding that was replicated in
our second trial (50). If APOE testing is utilized by
a significant number of consumers to inform their
LTC insurance purchasing, then insurers may be
within their rights to address this adverse selection
by increasing premiums or denying coverage based
on APOE results. Policymakers will then have to
decide whether to expand the Genetic Information
Non-discrimination Act to address not only health
insurance, but also other domains including LTC.
Study limitations
REVEAL findings should be interpreted with sev-
eral study limitations in mind. Treatment and pre-
vention options for AD are very limited compared
to those for many other common, complex condi-
tions. Indeed, expectations and attitudes about AD
susceptibility testing and responses to results dis-
closure may change dramatically as proven strate-
gies to reduce AD risk emerge. In addition, results
may not generalize to broader segments of the
population, given that participants were predom-
inantly of higher socioeconomic status and gener-
ally highly motivated to pursue risk information.
We also screened out participants who showed
moderate to severe psychiatric and/or cognitive
difficulties at baseline. Behavioral changes were



























Fig. 3. Proportion of participants in the first REVEAL
Study trial reporting insurance change during 12 months
following genetic risk disclosure, stratified by randomiza-
tion status/APOE genotype and insurance domain. APOE,
apolipoprotein E; REVEAL, Risk Evaluation and Education
for Alzheimer’s Disease.
up to 1 year following disclosure; future stud-
ies should seek more objective measures of these
domains, with longer term follow-up. Finally,
research presented here was conducted primarily in
the United States. There is limited cross-national
work in this area, although one survey comparing
the beliefs of Italians and Americans about genetic
susceptibility testing for AD suggested stronger
beliefs among Americans about the likelihood of
developing AD, greater AD knowledge, stronger
beliefs that susceptibility testing can help with
planning for the future, and greater fears about the
possibility of insurance and employment discrim-
ination (51). Such findings suggest that cultural
differences in lifestyles, social systems and health
policies may impact attitudes toward susceptibility
testing.
Future directions
Alternative service delivery models
The time-intensive, traditional genetic counseling
model will need to be adapted to accommodate
the needs of a growing number of patients seek-
ing genetic testing for adult-onset conditions (52).
Leaders in the field have called for a model of care
emphasizing briefer protocols and use of supple-
mentary educational media (53, 54). In this spirit,
the second REVEAL trial examined the impact of
a condensed clinical risk communication protocol
for first-degree relatives of people with AD, as
compared to the extended protocol developed in
our first trial. The condensed protocol was deliv-
ered in fewer sessions and required less face-to-
face time (mean = 33 vs 76 min) with the study
clinician. In addition, participants did not differ by
protocol in terms of depression and anxiety symp-
toms or by rates of risk recall and comprehension
at any point in the yearlong follow-up period (55).
We are also continuing to address emerging trends
in provision of genetic test results with ongoing
analyses of the third REVEAL trial, where tele-
phone disclosure of APOE results was compared
to an in-person model. The trial also examined the
impact of disclosure of pleiotropic disease risks
(i.e. AD and coronary artery disease) associated
with APOE.
Conclusion
Experts forecast that genetic susceptibility test-
ing for common adult-onset diseases will become
much more commonplace in the future, and AD
and APOE testing provide a fruitful paradigm in
which to examine its potential benefits and harms.
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Results indicate that many individuals are inter-
ested in genetic testing for non-medical reasons
and that provision of test results does not generally
result in adverse psychological effects if delivered
by trained professionals using appropriate educa-
tional approaches. Furthermore, our results sug-
gest that modifications to streamline the genetic
counseling process in this context can be made
without increasing the likelihood of participant dis-
tress or misunderstanding. However, our findings
also show numerous challenges associated with
the estimation and communication of genetic risk
for AD and they suggest a potential future need
to develop policies to address genetic discrimina-
tion in LTC insurance. Lessons from the REVEAL
Study may be useful to bear in mind as the field of
personal genomics continues to expand. However,
despite our attempts to keep pace with evolving
practices, the rapid pace of scientific discoveries
and commercial efforts to market genetic tests is
overwhelming our ability to generate a clinical
research evidence base to guide practice and pol-
icy. Already being provided are all-in-one personal
genomic services that include carrier screening,
pharmacogenetic tests, and susceptibility testing
for scores of health conditions. Understanding and
teasing apart reactions to genetic information pro-
vided in such a format will undoubtedly prove
vexing and may strain the limits of our traditional
clinical trials designs. Yet, such research will be
critical if we are to responsibly integrate genomic
discoveries into both healthcare and society at
large.
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